← Back to patent-cliff list
Tacrolimus (novaliq)
Tier C — Watch / tradeTacrolimus (novaliq)
Novaliq Gmbh
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Calcineurin, FKBP1A, Cytokines, BMPR2
Indications (approved)：前葡萄膜炎, Dry eye disease, 角结膜炎, 葡萄膜炎
Regional status
US
Phase II
2026-03-16
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tacrolimus (novaliq)?
Approved indications include: 前葡萄膜炎, Dry eye disease, 角结膜炎, 葡萄膜炎.
When does the Tacrolimus (novaliq) patent expire?
No public expiry year is available for Tacrolimus (novaliq) yet; this page updates once verified.
How do I get a quote for Tacrolimus (novaliq) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29